Industry News, Patient Care

FDA Warns Consumers Not to Use Off-brand Versions of Ozempic, Wegovy

June 2, 2023
Prescription

The U.S. Food and Drug Administration is warning consumers not to use off-brand versions of the popular weight-loss drugs Ozempic and Wegovy because they might not contain the same ingredients as the prescription products and may not be safe or effective.

Agency officials said this week that they have received reports of problems after patients used versions of semaglutide, the active ingredient in the brand-name medications, which have been compounded, or mixed in pharmacies. Officials didn’t say what the problems were.

The trouble is that those versions, often sold online, contain a version of semaglutide that is used in lab research and has not been approved for use in people.

“Compounded drugs are not FDA-approved, and the agency does not verify the safety or effectiveness of compounded drugs,” the notice said.

Read more at AP News >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor
    • Galderma’s Restylane Contour Gains FDA Approval for the Correction of Temple Hollowing